Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug TLC-6740 enters first human trials

NCT ID NCT05822544

Recruiting now Disease control Sponsor: OrsoBio, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called TLC-6740 in healthy volunteers and people with obesity, with or without type 2 diabetes. The main goals are to check safety, how the body processes the drug, and to get an early look at whether it helps with weight loss or blood sugar control. The study involves up to 564 participants and is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS OBESITY TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • OrsoBio Auckland Research Site 1

    RECRUITING

    Auckland, New Zealand

  • OrsoBio Auckland Research Site 2

    RECRUITING

    Auckland, New Zealand

  • OrsoBio Auckland Research Site 3

    RECRUITING

    Auckland, New Zealand

  • OrsoBio Research Site

    RECRUITING

    Christchurch, New Zealand